Introduction: Fingolimod is the first oral disease-modifying therapy (DMT) approved for relapsing-remitting multiple sclerosis (RRMS) (1). It works by modulating sphingosine-1-phosphate receptors to retain lymphocytes in lymph nodes, thereby reducing inflammation and the formation of new central nervous system lesions (1). Although fingolimod has d
460 Reached
Young Girl Presented with Irritability and Abnormal Behavior
2254 Reached10 Comments4 Likes
Management of Infantile Myoclonic Seizures
1169 Reached3 Comments3 Likes
Unconscious Male in ED following Loss of Motorcycle Control
828 Reached2 Comments2 Likes
Headache with Clinically Non-functioning Pituitary Adenoma
818 Reached1 Comments4 Likes
Safe Ramadan Practices during COVID-19 - WHO Guidance
6542 Reached8 Comments3 Likes